RenovoRx expands RenovoCath use and targets 2027 pancreatic cancer readout

RenovoRx is advancing its Trans-Arterial Micro-Perfusion (TAMP) platform, which aims to treat locally advanced pancreatic cancer by delivering chemotherapy directly to tumors via the FDA-cleared RenovoCath device. CEO Shaun Bagai stated the method is designed to increase local drug concentration while reducing the systemic toxicity typically associated with intravenous chemotherapy. The company is targeting a 2027 readout for its TIGeR-PaC study and has expanded the use of RenovoCath to 21 centers.

Financial analysts at HC Wainwright have issued Q3 2027 earnings estimates for the company, forecasting earnings per share of ($0.01). RenovoRx recently reported quarterly revenue of $0.91 million, exceeding consensus estimates. The company currently holds a market capitalization of approximately $63.07 million and maintains a consensus rating of 'Moderate Buy' among analysts.